Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress
Aptose Biosciences Inc (NASDAQ:APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials – one in relapsed or…
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease
Forma Therapeutics Holdings Inc (NASDAQ:FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease.…
Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer Trial
Protagonist Therapeutics Inc (NASDAQ:PTGX) has announced updated results from the ongoing Phase 2 study of rusfertide for polycythemia vera (PV), a…
Zynerba Pharmaceuticals Shares Spike After Co. Highlights Presentation Of Data From Zygel Study At Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric
Chemomab Therapeutics Is Heating Up And Could See A Move Soon
Chemomab Therapeutics LTD. (NASDAQ: CMMB) shares are trading higher Friday as retail traders continue to push stocks higher.
Graybug Vision Shorts Got A Serious Squeeze: What’s Next?
Graybug Vision Inc (NASDAQ: GRAY) has not released any news since it printed its first-quarter 2021 earnings results May 12, but that didn’t stop the stock fr
A Technical Look At Novan’s Stock Amid 80% Spike
Novan Inc. (NASDAQ: NOVN) shares are trading higher Friday after the company reported that B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved significance for the primary endpoint with no adverse events.